Erythropoietin: Still on the Neuroprotection Road

Overview

Journal Ther Adv Neurol Disord

Specialty Neurology

Date 2012 May 17

PMID 22590480

Citations 25

Authors

Nelvys Subiros

Diana Garcia Del Barco

Rosa M Coro-Antich

Affiliations

Soon will be listed here.

Abstract

Acute stroke is one of the major causes of death and disabilities. Since the 1980s many clinical studies have been conducted to evaluate neuroprotective approaches to treat this important brain vascular event. However, to date the only drug approved (recombinant tissue plasminogen activator [rtPA]) represents a thrombolytic, nonneuroprotective approach. An important neuroprotective strategy is based on erythropoietin (EPO). Exogenously administered EPO exhibits neuroprotective effects in numerous animal models, through the activation of anti-apoptotic, anti-oxidant and anti-inflammatory pathways as well as through the stimulation of angiogenic and neurogenic events. The capability of EPO to cross the blood-brain barrier after systemic administration and its effective therapeutic window are advantages for human acute stroke therapy. However, a multicenter stroke trial where recombinant human EPO (rhEPO) was combined with rtPA had negative outcomes. The present paper reviews the EPO neuroprotective strategy and its mechanisms in ischemic stroke and in other human nervous system diseases.

Citing Articles

Influences and mechanism of erythropoietin on the cognitive function of vascular dementia rats.

Tang Z, Li X, Yin N, Zhao M, Hu Q, Lv P Aging (Albany NY). 2023; 15(21):12264-12274.

PMID: 37934569 PMC: 10683607. DOI: 10.18632/aging.205178.

The Effects of a Blood-Brain Barrier Penetrating Erythropoietin in a Mouse Model of Tauopathy.

Yang J, Ou W, Jagadeesan N, Simanauskaite J, Sun J, Castellanos D Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111315 PMC: 10141171. DOI: 10.3390/ph16040558.

Erythropoietin Enhances Post-ischemic Migration and Phagocytosis and Alleviates the Activation of Inflammasomes in Human Microglial Cells.

Arik E, Heinisch O, Bienert M, Gubeljak L, Slowik A, Reich A Front Cell Neurosci. 2022; 16:915348.

PMID: 35813499 PMC: 9263298. DOI: 10.3389/fncel.2022.915348.

Neural Differentiation of Human Dental Mesenchymal Stem Cells Induced by ATRA and UDP-4: A Comparative Study.

Koutsoumparis A, Patsiarika A, Tsingotjidou A, Pappas I, Tsiftsoglou A Biomolecules. 2022; 12(2).

PMID: 35204719 PMC: 8961660. DOI: 10.3390/biom12020218.

Perspectives in the Cell-Based Therapies of Various Aspects of the Spinal Cord Injury-Associated Pathologies: Lessons from the Animal Models.

Zawadzka M, Kwasniewska A, Miazga K, Slawinska U Cells. 2021; 10(11).

PMID: 34831217 PMC: 8616284. DOI: 10.3390/cells10112995.

References

He J, Huang Z, Yang H, Weng K, Zhu S . [Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants]. Zhongguo Dang Dai Er Ke Za Zhi. 2008; 10(5):586-8. View

Tseng M, Hutchinson P, Richards H, Czosnyka M, Pickard J, Erber W . Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg. 2009; 111(1):171-80. DOI: 10.3171/2009.3.JNS081332. View

Sakanaka M, Wen T, Matsuda S, Masuda S, Morishita E, Nagao M . In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A. 1998; 95(8):4635-40. PMC: 22542. DOI: 10.1073/pnas.95.8.4635. View

Digicaylioglu M, Lipton S . Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001; 412(6847):641-7. DOI: 10.1038/35088074. View

Diaz Z, Assaraf M, Miller Jr W, Schipper H . Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders. J Neurochem. 2005; 93(2):392-402. DOI: 10.1111/j.1471-4159.2005.03038.x. View

Cramer S, Fitzpatrick C, Warren M, Hill M, Brown D, Whitaker L . The beta-hCG+erythropoietin in acute stroke (BETAS) study: a 3-center, single-dose, open-label, noncontrolled, phase IIa safety trial. Stroke. 2010; 41(5):927-31. PMC: 2869209. DOI: 10.1161/STROKEAHA.109.574343. View

Kilic E, Kilic U, Soliz J, Bassetti C, Gassmann M, Hermann D . Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. FASEB J. 2005; 19(14):2026-8. DOI: 10.1096/fj.05-3941fje. View

Savino C, Pedotti R, Baggi F, Ubiali F, Gallo B, Nava S . Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol. 2005; 172(1-2):27-37. DOI: 10.1016/j.jneuroim.2005.10.016. View

Campana W, Li X, Shubayev V, Angert M, Cai K, Myers R . Erythropoietin reduces Schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injury. Eur J Neurosci. 2006; 23(3):617-26. DOI: 10.1111/j.1460-9568.2006.04606.x. View

10.

Fisher M, Feuerstein G, Howells D, Hurn P, Kent T, Savitz S . Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009; 40(6):2244-50. PMC: 2888275. DOI: 10.1161/STROKEAHA.108.541128. View

11.

Mahmood A, Lu D, Qu C, Goussev A, Zhang Z, Lu C . Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg. 2007; 107(2):392-7. DOI: 10.3171/JNS-07/08/0392. View

12.

Liu W, Shen Y, Plane J, Pleasure D, Deng W . Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. Exp Neurol. 2011; 230(2):227-39. PMC: 3114206. DOI: 10.1016/j.expneurol.2011.04.021. View

13.

Fisher J . Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003; 228(1):1-14. DOI: 10.1177/153537020322800101. View

14.

Brines M, Patel N, Villa P, Brines C, Mennini T, De Paola M . Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008; 105(31):10925-30. PMC: 2504825. DOI: 10.1073/pnas.0805594105. View

15.

Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K . Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009; 40(12):e647-56. DOI: 10.1161/STROKEAHA.109.564872. View

16.

Chen G, Shi J, Hang C, Xie W, Liu J, Liu X . Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci Lett. 2007; 425(3):177-82. DOI: 10.1016/j.neulet.2007.08.022. View

17.

Wang X, Zhu C, Wang X, Gerwien J, Schrattenholz A, Sandberg M . The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem. 2004; 91(4):900-10. DOI: 10.1111/j.1471-4159.2004.02769.x. View

18.

Li F, Chong Z, Maiese K . Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Curr Neurovasc Res. 2006; 3(3):187-201. PMC: 1986678. DOI: 10.2174/156720206778018758. View

19.

Siren A, Fasshauer T, Bartels C, Ehrenreich H . Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics. 2008; 6(1):108-27. PMC: 5084260. DOI: 10.1016/j.nurt.2008.10.041. View

20.

Shuaib A, Hussain M . The past and future of neuroprotection in cerebral ischaemic stroke. Eur Neurol. 2007; 59(1-2):4-14. DOI: 10.1159/000109254. View